Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaplopurine in Crohn's disease: A meta-analysis. Ann Intern Med 1995; 122: 132-42.
Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343: 1249-52.
Feagan BG, Rochon J, Fedorak RN, et al. for The North American Crohn 's study group investigations. N Engl J Med 1995; 332: 292-7.
Sandborn WJ. A review of immune modifier therapy for IBD: Azathioprine. 6-mercaptopurine, cydosporin, and methotrexate. Am J Gastroenterol 1996; 91: 423-33.
D Van Dullemen HM, Van Deventer SJH, Hommes DW, et al. Treatment of Crohn 's disease with antitumor necrosis factor chimeric monochonal antibody (cA2). Gastroenterology 1995; 109: 129-35.
Targan S, Hanauer SB, Van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl J Med 1997; 337: 1029-35.
Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 1997; 349: 521-4.
Rutgeerts P, D'haens G, Van Deventer SJH, et al. Retreatment with anti-TNF α chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn's disease. Gastroenterology 1997; 112: A1078.
Van Deventer SJH, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Gastroenterology 1997; 113: 383-9.
Schreiber S, Fedorak RN, Nielsen OH, et al. A Safety and efficacy study of recombinant interleukin 10 (rHulL treatment in 329 patients with chronic active Crohn's disease (CACD). Gastroenterology 1998; 114: 04-123.
Van Deventer SJH, Camoglio O. Monoclonal antibody therapy of inflammatory bowel disease. Aliment Pharmacol Ther 1996; 10 (Suppl. 2): 107-11
Canva-Delcambre V, Jacipuot S, Robinet E, et al. Treatment of servere Crohn's disease with anti-CD4 monoclonal antibody. Aliment Pharmacol Ther 1996; 10: 721-7.
Yacyshyn B, Woloschuk MB, Yacyshin D, Martini K, Doan J. Efficacy and Safety of ISI 2302 (ICAM antisense oligonucleotide) treatment of steroid dependent CD. Gastroenterology 1997; 112: A1123.
Neurath MF, Pettersson F, Meyer zum Büschenfelde KH, Strober W. Local adminstration of antisense phosphorothioate oliganucleotides to the p65 subumit of NFκB abrogates established experimental colitis in mice Nature Med 1996; 2: 998-1004.
Sandborn WJ. Azathioprinc: State of the art in inflammatory bowel disease. Scand J Gastroenterol : 33(Suppl. 225): 92-9.
Barbe L, Martean P, Lemann M, et al. Dose raising of azathioprine beyond 2.5 mg/kg/day in Crohn's disease patients who fail to improve with a standard dose. Gastroenterology 1998; 114: G3794.
Sandborn WJ, Van Os EC, Zines BJ, et al. An intravenous loading dose of azahioprine decrease the time to response in patients with Crohn 's disease. Gastroenterology 1995; 109: 1808-17.
Louis E, Dupont E, Depaiov A, et al. Rapide ant-inflammatory effect of high dose disease azathioprine in inflammatary bowel disease: An in vitro study. Gastroentrology 998; 114 : G4206.
Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 21.1-9.
James S. Remission of Crohn's disease after human immunodeficiency vintv infection. Gastroente- rology 1988; 95: 1667-9.
Lopez-Cubero SO, Sullivari KM, McDonald GB. Course of Crohn's disease after allogeneic marrow trans- plantation. Gasteoterology 1998; 114: 433-40.